お知らせ • Mar 12
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy Oncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use. お知らせ • Mar 06
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies Oncology Pharma Inc. announced the initiation of formal drug development and preclinical planning for its lead drug product, based upon proprietary nanoemulsion technology licensed from NanoSmart Pharmaceuticals. Oncology Pharma will be providing the initial funds to develop and evaluate a dactinomycin nanoemulsion drug product. A version of this product originally received FDA Orphan Drug Designation in 2015.
Oncology Pharma has secured access to a broad range of proprietary intellectual property with the potential to make novel drug products to treat cancer that are both safer and more effective than the original drug(s) currently in the market. Oncology Pharma has initiated discussions with NanoSmart on near-term goals including analytical method validation and drug product characterization. Once complete, formal preclinical safety and veterinary clinical studies will be pursued. Veterinary drug development will serve a current and growing need for better treatment options. Data from this project may also be applied towards future regulatory approval to initial human clinical studies for the same drug formulation. お知らせ • Feb 27
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent Oncology Pharma Inc. announced that it has executed a world-wide Licensing Agreement with Sybleu Inc. for its Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agent. The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand. The concept of this invention is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.Oncology Pharma is excited about expanding its portfolio in oncology and therapeutics. The company sees a synergy within the portfolio and is continuously building within its expertise while utilizing its Board and Scientific Advisory Board to seek out opportunities to enhance its position within the field of oncology. お知らせ • Feb 23
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology Oncology Pharma, Inc. announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market. Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA). ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumor sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market. お知らせ • Feb 18
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board Oncology Pharma Inc. announced that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare. Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA tests for detecting cancer. In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells. He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career. Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England. お知らせ • Feb 10
Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform Oncology Pharma Inc. announced that it has renewed its world-wide Licensing Agreement with Ribera Solutions (under its tradename “Connect2Med”) with exclusivity for oncology, including drug development, clinical trials, personalized oncology and therapeutics. Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO, telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients’ workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI. お知らせ • Jan 29
Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer Oncology Pharma Inc. that it has retained the services of Mr. James Smith, CPA as its new Chief Financial Officer. Mr. James Smith, CPA is a seasoned executive officer with experience encompassing multiple public and private companies across a variety of industries. His prior experience includes CEO and/or CFO in two fully reporting SEC registrants as well as numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO capacities. In addition, during his employment with two national accounting firms and in his own CPA firm practice, Mr. Smith has worked with multiple Family Offices and investors in assisting them with their operations, capital placement, organizational strategy and structure, with an emphasis on tax and estate planning. Oncology Pharma is pleased to welcome Mr. Smith aboard as the Company is working towards expanding its portfolio and financing.